5-Fluorouridine

5-Fluorouridine

SCHEMBL329747

O=c1[nH]c(=O)n([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O)cc1F

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PYGM P11217 3/20 0.70
LMNA P02545 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
TSHR P16473 1/20 0.67
MAPT P10636 1/20 0.67
PMP22 Q01453 1/20 0.67
HBB P68871 1/20 0.67
TK2 O00142 2/20 0.65
P2RY6 Q15077 2/20 0.64
P2RY14 Q15391 2/20 0.64
NT5E P21589 1/20 0.64
SLC28A1 O00337 1/20 0.60
SLC28A2 O43868 1/20 0.60
SLC29A1 Q99808 1/20 0.60
SLC28A3 Q9HAS3 1/20 0.60
P2RY2 P41231 3/20 0.53
DNPH1 O43598 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Fluorouridine SCHEMBL19901621 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL1682759 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL214536 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL3385435 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL12174049 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL329381 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL17173362 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL11756887 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL21423048 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT
5-Fluorouridine SCHEMBL2584234 1.00 PYGM (0.70) PYGMLMNASMN1; SMN2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10882903-B2 Methods and compositions for treating an alphavirus infection ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-01-05 US disclosed
US-10869873-B2 Methods and compositions for treating viral diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-12-22 US disclosed
EP-2787999-B1 METHODS AND COMPOSITIONS FOR TREATING VIRAL DISEASES UNIV LELAND STANFORD JUNIOR (US) 2019-01-23 EP disclosed
US-20180134778-A1 METHODS AND COMPOSITIONS FOR TREATING AN ALPHAVIRUS INFECTION ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2018-05-17 US disclosed
US-20180000926-A1 METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS AGRAWAL, BABITA (CA) 2018-01-04 US disclosed
US-20170000802-A1 Methods and Compositions for Treating Viral Diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-01-05 US disclosed
CN-103145715-B Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors F·霍夫曼-罗须公司 2016-08-03 CN disclosed
US-9364484-B2 Methods and compositions for treating viral diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-06-14 US disclosed
EP-3025727-A1 METHODS OF TREATING LIVER DISEASE The J. David Gladstone Institutes (US) 2016-06-01 EP disclosed
US-9149463-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) 2015-10-06 US disclosed
WO-2006016930-A2 METHODS FOR TREATING HCV INFECTION INTERMUNE, INC. (US) 2006-02-16 WO disclosed
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication HOFFMANN-LA ROCHE INC. 2005-12-01 US disclosed
WO-2005110455-A2 COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION INTERMUNE, INC. (US) 2005-11-24 WO disclosed
WO-2005067454-A2 COMBINATION THERAPY FOR TREATING HEPATITIS C VIRUS INFECTION VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2005-07-28 WO disclosed
WO-2005067963-A1 USE OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON-ALPHA IN THERAPEUTIC DOSING REGIMENS INTERMUNE, INC. (US) 2005-07-28 WO disclosed
WO-2005062949-A2 METHOD FOR TREATING HEPATITIS VIRUS INFECTION INTERMUNE, INC. (US) 2005-07-14 WO disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 WO disclosed
EP-0788506-A2 L-RIBOFURANOSYL NUCLEOSIDES GENENCOR INTERNATIONAL, INC. (US) 1997-08-13 EP disclosed
US-5559101-A ANTITUMOR, ANTICARCINOGENIC, HIV GENENCOR INTERNATIONAL, INC. (US) 1996-09-24 US disclosed
WO-1996013512-A2 L-RIBOFURANOSYL NUCLEOSIDES GENENCOR INTERNATIONAL, INC. (US) 1996-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication EIF2AK2, HAVCR2, ZC3HAV1 PYGM 286/4885LMNA 625/4885SMN1; SMN2 748/4885
US-20180000926-A1 METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS HAVCR2, CD74, IFNG PYGM 1457/4885LMNA 4392/4885SMN1; SMN2 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.